Valsartan orodispersible tablets: Formulation, in vitro/in vivo characterization

AAPS PharmSciTech

Volumn 11, Issue 1, 2010, Pages 189-196

  Ibrahim, Howida Kamal ^a   El Setouhy, Doaa A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

33 full factorial design; Freeze drying technique; In vivo study; Orodispersible tablets; Valsartan

Indexed keywords

MANNITOL; PECTIN; VALSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FACTORIAL DESIGN; FREEZE DRYING; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SINGLE DRUG DOSE; SURFACE PROPERTY; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT;

ADULT; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSAGE FORMS; EXCIPIENTS; FREEZE DRYING; HUMANS; MALE; MIDDLE AGED; TABLETS; TETRAZOLES; VALINE;

EID: 77950918047     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9354-7     Document Type: Article

References (23)

1. M Leidig R Bambauer EJ Kirchertz T Szabã R Handrock D Leinung, et al. 2008 Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis Clin Nephrol 69 6 425 32 1:CAS:528:DC%2BD1cXosFWgsLo%3D 18538118
2. M Baumhäkel U Müller M Böhm 2008 Valsartan improves symptoms and quality of life in patients with chronic heart failure MMW Fortschr Med 150 Suppl 1 48 53 18540333
3. Flynn JT, Meyers KE, Neto JP, De Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222-8.
4. Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy, 3rd ed. Oxford University Press; 2002. p. 487-8.
5. Parfitt K. Martindale, The complete drug reference. 32nd, Pharmaceutical Press; 1999. p. 960.
6. M Rizwan M Aqil A Ahad Y Sultana MM Ali 2008 Transderrmal delivery of valsartan: I. Effect of various terpenes Drug Dev Ind Pharm 34 6 618 26 10.1080/03639040701833740 1:CAS:528:DC%2BD1cXnsVSqs7Y%3D 18568912 (Pubitemid 351878682)
7. European Pharmacopoeia; 4th ed., Suppl. 4.1. Council of Europe, Strasbourge, France; 2002. p. 2435.
8. Pierre H, Matthias S, Rosa M. Fast disintegrating oral dosage form.US Patent 6,083,531; 1998.
9. M Gohel M Patel A Amin R Agrawal R Dave N Bariya 2004 Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique AAPS PharmSciTech 5 3 e36 10.1208/pt050336 15760070
10. W Habib R Khankari J Hontz 2000 Fast-dissolving drug delivery systems, critical review in therapeutics Drug Carrier Systems 17 1 61 72 1:CAS:528:DC%2BD3cXis1Sitbk%3D
11. RK Chang X Guo B Burnside R Couch 2000 Fast-dissolving tablets Pharm Technol 24 6 52 8 1:CAS:528:DC%2BD3cXksl2lur8%3D
12. Clarke A, Brewer F, Johnson ES, Kelly EA. Proceeding of the 122nd Annual Meeting of the American Neurological Association, 1997, M69.
13. H Seager 1998 Drug-delivery products and the Zydis fast-dissolving dosage form J Pharm Pharmacol 50 375 82 1:CAS:528:DyaK1cXjsVyls7c%3D 9625481
14. Y Javadzadeh MR Siahi-Shadbad M Barzegar-Jalali A Nokhodchi 2005 Enhancement of dissolution rate of piroxicam using liquisolid compacts I I Farmaco 60 4 361 5 10.1016/j.farmac.2004.09.005 1:CAS:528:DC%2BD2MXjsVGrsro%3D (Pubitemid 40545953)
15. KA Khan CT Rhodes 1972 Effect of compaction pressure on the dissolution efficiency of direct compression systems Pharm Acta Helv 47 597 607
16. Y Bi H Sunada Y Yonezawa K Danjo A Otsuka K Iida 1996 Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity Chem Pharm Bull (Tokyo) 44 2121 7 1:CAS:528:DyaK28Xnt1yjt7o%3D
17. E Satana S AltInay NG Göger SA Özkan Z Sentürk 2001 J Pharm Biomed Anal 25 5-6 1009 13 10.1016/S0731-7085(01)00394-6 1:CAS:528:DC%2BD3MXjslektbs%3D 11377086 (Pubitemid 32488968)
18. S Corveleyn JP Remon 1997 Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug Int J Pharm 152 215 25 10.1016/S0378-5173(97)00092-6 1:CAS:528: DyaK2sXkslSqs7w%3D (Pubitemid 27290596)
19. th edition, Hanson, GR, Lippincott Williams; 2002. p.142.
20. PA Thurmann 2000 A novel anginotensin type1 receptor antagonist Expert Opin Pharmacother 1 2 337 50 10.1517/14656566.1.2.337 1:CAS:528: DC%2BD3cXntFSrug%3D%3D 11249553
21. G Flesch P Muller P Lloyd 1997 Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man Eur J Clin Pharmacol 52 2 115 20 10.1007/s002280050259 1:CAS:528:DyaK2sXjsVCgu7w%3D 9174680 (Pubitemid 27239595)
22. N Daneshtalab RZ Lewanczuk F Jamali 2002 High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method J Chromatogr B 766 345 9 10.1016/S0378-4347(01)00507-2 1:CAS:528:DC%2BD38Xls1Cktw%3D%3D (Pubitemid 34142367)
23. J Macek J Klima P Ptacek 2006 Rapid determination of valsartan in human plasma by protein precipitation and high performance liquid chromatography J Chromatogr B 832 169 72 10.1016/j.jchromb.2005.12.035 1:CAS:528: DC%2BD28Xhtlartro%3D (Pubitemid 43213025)